药康生物: 关于公司2025年半年度利润分配预案的公告

Core Viewpoint - The company plans to distribute a cash dividend of RMB 0.30 per 10 shares (including tax) based on its 2025 semi-annual financial performance, with a total cash dividend amounting to RMB 12,269,719.14, which represents 17.30% of the net profit attributable to shareholders for the period [1]. Summary by Sections Profit Distribution Plan - The company reported a net profit attributable to shareholders of RMB 70,905,477.14 for the first half of 2025, with the parent company's net profit at RMB 40,466,440.18 [1]. - As of June 30, 2025, the parent company's distributable profits amounted to RMB 353,380,864.98 [1]. - The total share capital as of June 30, 2025, was 410,000,000 shares, with 1,009,362 shares held in the repurchase account, leading to a base of 408,990,638 shares for the dividend distribution [1]. - The proposed cash dividend distribution will not include stock dividends or capital reserve transfers [1]. Decision-Making Process - The company's board of directors held a meeting on August 21, 2025, where the profit distribution plan was approved and deemed compliant with the company's profit distribution policy and shareholder return plan [2]. - The supervisory board also convened on the same day and approved the profit distribution plan, affirming that it considers the company's profitability, cash flow, and funding needs while ensuring reasonable returns for shareholders, particularly minority shareholders [3].